Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2007-07-10
2007-07-10
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C558S248000
Reexamination Certificate
active
11180332
ABSTRACT:
The present invention provides propofol prodrugs, methods of making propofol prodrugs, pharmaceutical compositions of propofol prodrugs and methods of using propofol prodrugs and pharmaceutical compositions thereof to treat or prevent diseases or disorders such as migraine headache pain and post-chemotherapy or post-operative surgery nausea and vomiting.
REFERENCES:
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 4765539 (1988-08-01), Noakes et al.
patent: 4962885 (1990-10-01), Coffee
patent: 5112598 (1992-05-01), Biesalski
patent: 5556611 (1996-09-01), Biesalski
patent: 5698155 (1997-12-01), Grosswald et al.
patent: 5950619 (1999-09-01), van der Linden et al.
patent: 5954047 (1999-09-01), Armer et al.
patent: 5970974 (1999-10-01), van der Linden et al.
patent: 6254853 (2001-07-01), Hendler et al.
patent: 6362234 (2002-03-01), Hendler
patent: 2001/0025035 (2001-09-01), Stella et al.
patent: WO 94/12285 (1994-06-01), None
patent: WO 94/14543 (1994-07-01), None
patent: WO 95/26234 (1995-10-01), None
patent: WO 95/26235 (1995-10-01), None
patent: WO 95/32807 (1995-12-01), None
patent: WO 99/58555 (1999-11-01), None
patent: WO 9958555 (1999-11-01), None
patent: WO 00/48572 (2000-08-01), None
patent: WO 00/54588 (2000-09-01), None
patent: WO 01/20331 (2001-03-01), None
patent: WO 02/13810 (2002-02-01), None
patent: WO 2004/033424 (2004-04-01), None
Adibi, “The oligopeptide transporter (Pept-1) in Human Intestine: Biology and Function,”Gastroenterology1997, 113, 332-340.
Alderman, “A Review of cellulose Ethers in Hydrophilic Matrices dor Oral controlled-Release Dosage Forms,”Int. J. Pharm. Tech. &Prod. Mfr. 1984, 5(3) 1-9.
Anderson et al., “Alpha-amino acid phenolic ester derivatives: novel water-soluble general anesthetic agents which allosterically modulate GABA(A) receptors,”J. Med. Chem. 2001, 44, 3582-3591.
Bamba et al., “Release Mechanisms in Gelforming Sustained Release Preparations,”Int. J. Pharm. 1979, 2, 307.
Banaszczyk et al., “Propofol Phosphate, a Water-Soluble Propofol Prodrug: In Vivo Evaluation,”Anesth. Analg. 2002, 95, 1285-1292.
Borgeat et al., “Preliminary Communication: Adjuvant Propofol Enables Better Control of Nausea and Emesid Secondary to Chemotherapy for Breast Cancer,”Can. J. Anaesth. 1994, 41, 1117-1119.
Borgeat et al., “Propofol improves patient comfort during cisplatin chemotherapy. A pilot study,”Oncology1993, 50, 456-459.
Briggs et al., “An Adverse Rection to the Administration of Disoprofol (Diprvan),”Anaesthesia1982, 37, 1099-1101.
Brooker at al., “Propofol Maintenance to Reduce Postoperatiove Emesis in Thyroidectomy Patients: A Group Sequential Comparison with Isoflurane/Nitrous Oxide,”Anaesth. Intensive Care1998, 26, 625-629.
Brown et al., “Role of Propofol in Refractory Status Epilepticus,”Pharmacother. 1998, 32, 1053-1059.
De la Cruz et al., “The Effect of Propofol on Oxidative Stress in Platelets from Surgical Patients,”Anesth. Analg. 1999, 89, 1050-1055.
During et al., “Controlled release of dopamine from a polymeric brain implant: in vivo characterization,” 1989,Ann. Neurol. 25:351.
Gan et al., “Determination of Plasma Concentrations of Propofol Associated with 50% Reduction in Postoperative Nausea,”Anesthesiology. 1997, 87, 779-784.
Hasan et al., “Comparison of the Effects of the Propofol and Thiopental on the Pattern of Maximal Electroshock Seizures in a Rat,”Pharmacol. Toxicol. 1994, 74, 50-53.
Hashimoto et al., “Abnormal Activity in the Globus Pallidus in the Off-Period Dystonia,”Annals. of Neurology, 2001, 49. 242-275.
Holtkamp et al., “Propofol in subanesthetic doses terminates status epilepticus in a rodent model,”Ann. Neurol. 2001, 49, 260-263.
Howard et al., “Intercerebral Drug Delivery in Rats with Lesion-Induced Memory Deficits,” 1989,J. Neurosurg. 71:105-112.
Krusz et al., “Intravenous Propofol: Unique Effectiveness in Treating Intractable Migraine,”Headache 2000, 40, 224-230.
Kuisma et al., “Propofol in Prewhospital Treatment of Convulsive Status Epilepticus,”Epilepsia1995, 36, 1241-1243.
Langer et al., “Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review,”J Macromol. Sci. Rev. Macromol Chem. 1983, 23:61.
Langley et al., “Propofol. A review of its pharmacodynamic and pharmacokinetic properties and use as an intravenous anaesthetic,”Drugs1988, 35, 334-372.
Leibach et al., “Peptide transporters in the intestine and the kidney,”Ann. Rev. Nutr. 1996, 16, 99-119.
Levy et al., “Inhibition of Calcification of Bioprosthetic Heart Valves by Local Controlled-Release Diphosphonate,”Science1985 228: 190-192.
Murphy et al., “The Antioxideant Potential of Propofol (2,6-Diisopropylphenol),”Br. J. Anaesth. 1992, 68, 613-618.
Peduto et al., “Biochemical and Electrophysiologic Evidence that Propofol Enhances GABAergic Transmission in the Rat Brain,”Anesthesiology1991, 75, 1000-1009.
Phelps, et al., “Propofol in Chemotherapy-Associated Nausea and Vomiting,”Ann Pharmacother, 1996, 30(3):290-292.
Picard, et al., “Prevention of Pain on Injection with Propofol: A Quantitative Systematic Review,”Anesth. Analg., 2000, 90:963-969.
Pop, et al., “Syntheses and Preliminary Pharmacological Evaluation of Some Chemical Delivery Systems of 2,6-diisopropylphenol (Propofol),”Med. Chem. Res., 1992, 2(1):16-21.
Raleigh et al., “Searching for the Link Between Hypoxia and Poor Prognoses in Human Tumors,”Proc. Amer. Assoc. Cancer Research Annual Meeting, 1999, 40, 397.
Raleigh et al., “Pharmacokinetics of Isotretinoin (ISO) in Rats Following Oral Dosing or Aerosol Inhalation,”British J. Cancer, 1999, 80, Suppl. 2, 96-97.
Raoof, et al., “In Vivo Assessment of Intestinal, Hepatic, and Pulmonary First Pass Metobolism of Propofol in the Rat,”Pharm Res. 1996, 13(6): 891-895.
Sagara, et al., “Propofol Hemisuccinate Protects Neuronal Cells from Oxidative Injury,”J Neurochem., 1999, 73(6):2524-2530.
Saudek et al., “A Preliminary Trial of the Programmable Implantable Medication System for Insulin Delivery,”N. Engl. J. Med., 1989, 321:574.
Sefton, “Implantable Pumps,”CRC Crit Ref Biomed. Eng. 1987, 14:201-240.
Simonian, et al., “Oxidative Stress in Neurodegenerative Diseases,”Pharmacol. Toxicol., 1996, 36:83-106.
Sutherland et al., “Propofol and Seizures,”Anaesth. Intensive Care, 1994, 22, 733-737.
Tomioka, et al., “Propofol is Effective in Chemotherapy-Induced Nausea and Vomiting: A Case Report with Quantitative Analysis,”Anesth. Analg., 1999, 89:798-799.
Tramer, et al., “Propofol anaesthesia and postoperative nausea and vomiting: quantitative systematic review of randomized controlled studies,”Br J Anasth, 1997, 78:247-255.
Trapani et al., “Water-Soluble Salts of Aminoacid Esters of the Anaesthetic Agent Propofol,”Int. J. Pharm. 1998, 175, 195-204.
Trapini, et al., “Propofol Analogues. Synthesis, Relationships between Structure and Affinity at GABAAReceptor in Rat Brain, and Differential Electrophysiological Profile at Recombinant Human GABAAReceptors,”J. Med. Chem., 1998, 41:1846-1854.
Verma et al., “Osmotically Controlled Oral Drug Delivery,”Drug Dev. Ind. Pharm., 2000, 26:695-708.
Walder et al., “Seizure-like phenomena and propofol: A systematic review,”Neurology2002, 58, 1327-1332.
Wang et al. “Propofol reduces infarct size and striatal dopamine accumulation following transient middle cerebral artery occlusion: a microdialysis study,”Eur. J. Pharmacol. 2002, 452, 303-308.
Young et al., “Propofol neuroprotection in a rat model of ischaemia reperfusion injury,
Gallop Mark A.
Xu Feng
Dorsey & Whitney LLP
Kosack Joseph R.
Saeed Kamal A.
Worrall Timothy A.
XenoPort, Inc.
LandOfFree
Prodrugs of propofol, compositions and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prodrugs of propofol, compositions and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prodrugs of propofol, compositions and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3738819